RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immunodiagnostic Systems Holdings Stock

Immunodiagnostic Systems Holdings ROA 2024

Immunodiagnostic Systems Holdings ROA

0

Ticker

IDH.L

ISIN

GB00B01YZ052

WKN

A0D9MS

In 2024, Immunodiagnostic Systems Holdings's return on assets (ROA) was 0, a 0% increase from the 0 ROA in the previous year.

Immunodiagnostic Systems Holdings Aktienanalyse

What does Immunodiagnostic Systems Holdings do?

IDS, Immunodiagnostic Systems Holdings PLC, is an English-American diagnostic company that specializes in the development, manufacture, and marketing of diagnostic tests for various applications. The company was founded in 1977 in Boldon, England and is headquartered in Tyne and Wear. IDS started with a focus on researching enzyme immunoassays (EIA) and has expanded its offerings to include radioimmunoassays and chemiluminescent tests. IDS operates in sectors such as endocrinology, clinical chemistry, hematology, and oncology, and is known as a leading provider of diagnostic test kits in many countries. The company offers over 400 tests, including reagents, calibrators, controls, and devices for more than 200 different parameters. IDS sells its products through an international network of branches, distributors, and authorized dealers in Asia, Europe, North America, South America, and the Middle East. The company has also established subsidiaries in the US and China to expand its offerings and drive growth in these regions. IDS's business model is focused on meeting customer needs for reliable, accurate, and fast diagnostic solutions. The company adheres to the highest quality standards and is committed to the continuous development and improvement of its products to enhance patient care and laboratory work worldwide. IDS has made a name for itself in the diagnostic industry in recent years and is a pioneer in developing tests for emerging applications such as autoimmune diseases and food intolerances. The company invests heavily in research and development and collaborates closely with academic partners and research institutions to identify and develop innovative diagnostic solutions. In summary, IDS is a leading diagnostic company operating in various applications and offering a wide range of diagnostic test solutions. The company has experienced strong growth in recent years and is committed to expanding its product range and offerings to meet the needs of patients and laboratories worldwide. Immunodiagnostic Systems Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Immunodiagnostic Systems Holdings's Return on Assets (ROA)

Immunodiagnostic Systems Holdings's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Immunodiagnostic Systems Holdings's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Immunodiagnostic Systems Holdings's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Immunodiagnostic Systems Holdings’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Immunodiagnostic Systems Holdings stock

What is the Return on Assets (ROA) of Immunodiagnostic Systems Holdings this year?

The Return on Assets (ROA) of Immunodiagnostic Systems Holdings is 0 undefined this year.

What was the ROA of Immunodiagnostic Systems Holdings compared to the previous year?

The ROA of Immunodiagnostic Systems Holdings has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of Immunodiagnostic Systems Holdings?

A high ROA is advantageous for investors of Immunodiagnostic Systems Holdings, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Immunodiagnostic Systems Holdings?

A low ROA can be unfavorable for investors of Immunodiagnostic Systems Holdings as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Immunodiagnostic Systems Holdings affect the company?

An increase in ROA of Immunodiagnostic Systems Holdings can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Immunodiagnostic Systems Holdings impact the company?

A reduction in the ROA of Immunodiagnostic Systems Holdings can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Immunodiagnostic Systems Holdings?

Some factors that can influence the ROA of Immunodiagnostic Systems Holdings include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Immunodiagnostic Systems Holdings important for investors?

The ROA of Immunodiagnostic Systems Holdings is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Immunodiagnostic Systems Holdings take to improve ROA?

To improve ROA, Immunodiagnostic Systems Holdings can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Immunodiagnostic Systems Holdings pay?

Over the past 12 months, Immunodiagnostic Systems Holdings paid a dividend of 0.02 GBP . This corresponds to a dividend yield of about 50.26 %. For the coming 12 months, Immunodiagnostic Systems Holdings is expected to pay a dividend of 0.02 GBP.

What is the dividend yield of Immunodiagnostic Systems Holdings?

The current dividend yield of Immunodiagnostic Systems Holdings is 50.26 %.

When does Immunodiagnostic Systems Holdings pay dividends?

Immunodiagnostic Systems Holdings pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Immunodiagnostic Systems Holdings?

Immunodiagnostic Systems Holdings paid dividends every year for the past 15 years.

What is the dividend of Immunodiagnostic Systems Holdings?

For the upcoming 12 months, dividends amounting to 0.02 GBP are expected. This corresponds to a dividend yield of 50.26 %.

In which sector is Immunodiagnostic Systems Holdings located?

Immunodiagnostic Systems Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunodiagnostic Systems Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunodiagnostic Systems Holdings from 8/14/2020 amounting to 0.019 GBP, you needed to have the stock in your portfolio before the ex-date on 7/16/2020.

When did Immunodiagnostic Systems Holdings pay the last dividend?

The last dividend was paid out on 8/14/2020.

What was the dividend of Immunodiagnostic Systems Holdings in the year 2023?

In the year 2023, Immunodiagnostic Systems Holdings distributed 0.007 GBP as dividends.

In which currency does Immunodiagnostic Systems Holdings pay out the dividend?

The dividends of Immunodiagnostic Systems Holdings are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunodiagnostic Systems Holdings

Our stock analysis for Immunodiagnostic Systems Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunodiagnostic Systems Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.